The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Tandem Meetings 2023 | Incorporating immunotherapy in the frontline & salvage treatment of Hodgkin lymphoma
Swetha Kambhampati, MD, City of Hope, Duarte, CA, comments on the benefit of adding novel agents such as brentuximab vedotin and checkpoint inhibitors like nivolumab into the frontline treatment of Hodgkin lymphoma (HL). The ECHELON-1 (NCT01712490) study reported an overall survival (OS) advantage for patients treated with A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) when compared to ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) alone. An ongoing study (NCT03907488) is now comparing brentuximab vedotin or nivolumab with chemotherapy in HL. Dr Kambhampati also comments on the benefit of these immunotherapeutic agents in the salvage setting, where they have been shown to improve chemosensitivity. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
